{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:38:36Z","timestamp":1776825516170,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300437"],"award-info":[{"award-number":["NIHR300437"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dysphagia"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent oropharyngeal cancer (rOPC) presents challenging treatment decision-making. Toxicity from previous treatment, coupled with potential functional and quality of life (QoL) morbidity of further treatment(s) can influence decision-making regarding curative and non-curative treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate swallowing and QoL outcomes, treatment-related priorities, and patient experience before and after rOPC treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Longitudinal, multicentre, mixed method study. Outcomes included the MD Anderson Dysphagia Inventory (MDADI), Performance Status Scale for Head and Neck Cancer (PSS-HN), the University of Washington QoL Questionnaire (UWQoLv4), the Chicago Priority Scale (CPS) and semi-structured interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The sample included 37 participants (prospective\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925, retrospective\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912, females\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) with a median age of 63 (range 41\u201388). The majority (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921) had curative intent treatment (surgery\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920 or radiation\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). The remainder had non-curative intent immunotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914) or chemotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). Swallowing and QoL were impaired at baseline; median MDADI composite score: 60 (IQR: 52.15\u201381.75), median PSS- HN normalcy of diet: (NoD): 50 and UWQoLv4 global health score (GHS): 60 (IQR 40\u201360). The PSS-HN NoD score deteriorated to 40 at six months. The MDADI and UWQoL data remained impaired. Triangulation with qualitative data revealed agreement with the PSS data and provided context for the relatively stable QoL. Being cured of cancer and living as long as possible remained the key priorities at all timepoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study swallowing deteriorated with treatment for rOPC. Treatment-related priorities remained focused on cure or survival. If the treatment-related goal was achieved, patients adapted and experienced at least stable QoL regardless of swallowing status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00455-025-10898-0","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:23:45Z","timestamp":1764825825000},"page":"473-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Swallowing and QoL Outcomes, Patient Experience and Treatment Related Priorities in Recurrent Oropharyngeal Cancer (rOPC)- a Mixed Method Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-1675","authenticated-orcid":false,"given":"Grainne","family":"Brady","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinidh","family":"Paleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernilla","family":"Lagergren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"9","key":"10898_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/0284186X.2020.1759822","volume":"59","author":"J Asheer","year":"2020","unstructured":"Asheer J, et al. Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review. Acta Oncol. 2020;59(9):1131\u20136.","journal-title":"Acta Oncol"},{"issue":"5","key":"10898_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/hed.26100","volume":"42","author":"J Hardman","year":"2020","unstructured":"Hardman J, et al. Transoral robotic surgery for recurrent cancers of the upper aerodigestive tract-systematic review and meta-analysis. Head Neck. 2020;42(5):1089\u2013104.","journal-title":"Head Neck"},{"issue":"3","key":"10898_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MOO.0000000000000620","volume":"28","author":"GC Brady","year":"2020","unstructured":"Brady GC, et al. Changing paradigms in the treatment of residual\/recurrent head and neck cancer: implications for dysphagia management. Curr Opin Otolaryngol Head Neck Surg. 2020;28(3):165\u201371.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"S2","key":"10898_CR4","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1017\/S002221511600061X","volume":"130","author":"H Mehanna","year":"2016","unstructured":"Mehanna H, Kong A, Ahmed S. Recurrent head and neck cancer: united Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S181-90.","journal-title":"J Laryngol Otol"},{"issue":"12","key":"10898_CR5","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/hed.24531","volume":"38","author":"SC Jayaram","year":"2016","unstructured":"Jayaram SC, et al. Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent\/residual oropharyngeal carcinoma: a systematic review and meta-analysis. Head Neck. 2016;38(12):1855\u201361.","journal-title":"Head Neck"},{"key":"10898_CR6","doi-asserted-by":"publisher","first-page":"104526","DOI":"10.1016\/j.oraloncology.2019.104526","volume":"102","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald V, et al. Global treatment patterns and outcomes among patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results of the GLANCE H&N study. Oral Oncol. 2020;102:104526.","journal-title":"Oral Oncol"},{"issue":"10167","key":"10898_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EE Cohen","year":"2019","unstructured":"Cohen EE, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156\u201367.","journal-title":"Lancet"},{"issue":"10212","key":"10898_CR8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"issue":"4","key":"10898_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41(4):790\u2013802.","journal-title":"J Clin Oncol"},{"issue":"3","key":"10898_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433330","volume":"44","author":"AJ Rosenberg","year":"2024","unstructured":"Rosenberg AJ, et al. Breaking ground in recurrent or metastatic head and neck squamous cell carcinoma: novel therapies beyond PD-L1 immunotherapy. Am Soc Clin Oncol Educ Book. 2024;44(3):e433330.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10898_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/ACS-230001","volume":"26","author":"G Brady","year":"2023","unstructured":"Brady G, et al. Patient experience, functional and quality of life outcomes in patients receiving surgical and non-surgical treatment for residual, recurrent, or new oropharyngeal cancer in a previously irradiated field: a systematic review. Advances in Communication and Swallowing. 2023;26:109\u201323.","journal-title":"Advances in Communication and Swallowing"},{"key":"10898_CR12","unstructured":"Creswell JW, Clark VLP. Designing and conducting mixed methods research. Sage; 2017."},{"issue":"2","key":"10898_CR13","first-page":"281","volume":"12","author":"AJ Onwuegbuzie","year":"2007","unstructured":"Onwuegbuzie AJ, Collins KM. A typology of mixed methods sampling designs in social science research. Qual Rep. 2007;12(2):281\u2013316.","journal-title":"Qual Rep"},{"key":"10898_CR14","unstructured":"Chen AY, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the MD Anderson dysphagia inventory. Volume 127. Archives of Otolaryngology\u2013Head & Neck Surgery; 2001. pp. 870\u20136. 7."},{"issue":"11","key":"10898_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S","volume":"77","author":"MA List","year":"1996","unstructured":"List MA, et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: a study of utility and validity. Cancer. 1996;77(11):2294\u2013301.","journal-title":"Cancer"},{"issue":"6","key":"10898_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hed.10106","volume":"24","author":"SN Rogers","year":"2002","unstructured":"Rogers SN, et al. The addition of mood and anxiety domains to the university of Washington quality of life scale. Head Neck. 2002;24(6):521\u20139.","journal-title":"Head Neck"},{"issue":"6","key":"10898_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/(SICI)1097-0347(199909)21:6<538::AID-HED7>3.0.CO;2-Z","volume":"21","author":"HM Sharp","year":"1999","unstructured":"Sharp HM, et al. Patients\u2019 priorities among treatment effects in head and neck cancer: evaluation of a new assessment tool. Head Neck. 1999;21(6):538\u201346.","journal-title":"Head Neck"},{"issue":"2","key":"10898_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoto.2024.3757","volume":"151","author":"G Brady","year":"2025","unstructured":"Brady G, et al. Patient and caregiver experience of diagnosis, treatment, and living with recurrent oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2025;151(2):97\u2013104.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10898_CR19","doi-asserted-by":"crossref","unstructured":"Ritchie J, Spencer L. Bryman A, Burgess RD. Qualitative data analysis for applied policy research. Analyzing qualitative data, 1994: pp. 173\u2013194.","DOI":"10.4324\/9780203413081_chapter_9"},{"issue":"6 Pt 2","key":"10898_CR20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs-principles and practices. Health Serv Res. 2013;48(6 Pt 2):2134\u201356.","journal-title":"Health Serv Res"},{"issue":"8","key":"10898_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1470-2045(23)00265-6","volume":"24","author":"C Nutting","year":"2023","unstructured":"Nutting C, et al. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial. Lancet Oncol. 2023;24(8):868\u201380.","journal-title":"Lancet Oncol"},{"issue":"1","key":"10898_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1598-x","volume":"15","author":"W Owadally","year":"2015","unstructured":"Owadally W, et al. PATHOS: a phase II\/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer. 2015;15(1):1\u201310.","journal-title":"BMC Cancer"},{"issue":"5","key":"10898_CR23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ijrobp.2008.10.047","volume":"73","author":"J-L Lefebvre","year":"2009","unstructured":"Lefebvre J-L, Ang KK, Panel LPC. Larynx preservation clinical trial design: key issues and recommendations\u2014a consensus panel summary. Int J Radiation Oncology* Biology* Phys. 2009;73(5):1293\u2013303.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"6","key":"10898_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jamaoto.2016.0656","volume":"142","author":"AD Falchook","year":"2016","unstructured":"Falchook AD, et al. Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517\u201323.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"10898_CR25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/1754-9485.13048","volume":"64","author":"H Nguyen","year":"2020","unstructured":"Nguyen H, et al. Using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine head and neck cancer care: what do health professionals perceive as barriers and facilitators? J Med Imaging Radiat Oncol. 2020;64(5):704\u201310.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10898_CR26","volume-title":"Assessment of patients with head and neck cancer using the MD Anderson dysphagia inventory: results of a study into its comprehensiveness, comprehensibility and relevance to clinical practice","author":"K Toft","year":"2024","unstructured":"Toft K, Best C, Donaldson J. Assessment of patients with head and neck cancer using the MD Anderson dysphagia inventory: results of a study into its comprehensiveness, comprehensibility and relevance to clinical practice. n\/a(n\/a): International Journal of Language & Communication Disorders; 2024."},{"key":"10898_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.05.005","author":"L McDowell","year":"2024","unstructured":"McDowell L, et al. A hard truth to swallow: critically evaluating the MD Anderson dysphagia inventory (MDADI) as an endpoint in human Papillomavirus-associated oropharyngeal cancer trials. Int J Radiat Oncol Biol Phys. 2024;120(3):805\u201322. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.05.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10898_CR28","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","volume":"48","author":"MA Sprangers","year":"1999","unstructured":"Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507\u201315.","journal-title":"Soc Sci Med"}],"container-title":["Dysphagia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00455-025-10898-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00455-025-10898-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00455-025-10898-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:59:47Z","timestamp":1776823187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00455-025-10898-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10898"],"URL":"https:\/\/doi.org\/10.1007\/s00455-025-10898-0","relation":{},"ISSN":["0179-051X","1432-0460"],"issn-type":[{"value":"0179-051X","type":"print"},{"value":"1432-0460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study protocol was approved by the Royal Marsden NHS Foundation Trust Committee for Clinical Research (CCR5242) and the Health Research Authority (HRA) (IRAS: 297893).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Professor Vinidh Paleri is a proctor for Intuitive Medical Inc. The other authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"I can confirm that the study participants quoted provided informed consent (permission) to be recorded and for their self-identifiable quotes to be published. Written informed consent was obtained for all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}